EMA Working On New Guidance For Infectious And Respiratory Diseases, Biosimilars
Executive Summary
Companies can expect to see a number of finalized and draft EU guidelines published throughout 2018 and into 2019, according to newly published work plans for the European Medicines Agency’s Infectious Disease Working Party, Biosimilar Medicinal Products Working Party and the Respiratory Drafting Group.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.